Physiogenex
  • About Us
    • Company overview
    • Management Team
    • Our values
    • Facilities
    • Partners
  • CRO Services
    • Obesity – Insulin Resistance – Diabetes
    • NASH – Fibrosis
    • Diabetic Nephropathy
    • Fibrosis
    • Diabetic Neuropathy
    • GLP-1 Expertise
    • Immunometabolism
    • Dyslipidaemia Atherosclerosis
    • Nutraceuticals
    • Covid-19
  • Capabilities
    • In vivo metabolic studies
    • Ex vivo metabolic assays
    • Biochemical assays and histology analysis
    • Biological samples library
  • Consulting
  • Publications
  • News
  • careers
    • Spontaneous Application
    • Careers at Physiogenex
  • Contact us
Select Page
Physiogenex to present its obese NASH hamster model at the 6th Obesity & NASH Summit in Boston, MA, Nov. 30- Dec. 1, 2022

Physiogenex to present its obese NASH hamster model at the 6th Obesity & NASH Summit in Boston, MA, Nov. 30- Dec. 1, 2022

by François Briand | Nov 22, 2022 | 2022

Physiogenex will be presenting its innovative obese NASH hamster model at the 6th Obesity and NASH Summit in Boston, MA, USA, Nov. 30th – Dec.1st, 2022. This unique preclinical model will be presented during an oral presentation on Dec. 1st at 11:30am and the...
Physiogenex to present its obese NASH hamster model at the AFDD Summit in Boston, MA, Nov. 10-11, 2022

Physiogenex to present its obese NASH hamster model at the AFDD Summit in Boston, MA, Nov. 10-11, 2022

by François Briand | Nov 9, 2022 | 2022

Physiogenex will be presenting its innovative obese NASH hamster model at the AFDD (AntiFibrotic Drug Development) Summit in Boston, MA, USA, Nov. 10-11th, 2022. This unique preclinical model will be presented during an oral presentation and the poster session on...
Physiogenex to present its obese NASH hamster model at the AASLD Liver Meeting 2022 in Washington D.C., Nov. 4-8

Physiogenex to present its obese NASH hamster model at the AASLD Liver Meeting 2022 in Washington D.C., Nov. 4-8

by François Briand | Oct 28, 2022 | 2022

Physiogenex will be presenting 2 novel studies in its innovative obese NASH hamster model at the AASLD Liver Meeting in Washington D.C., USA, Nov. 4-8th, 2022. Studies will be presented during the poster session of Saturday November the 5th, posters #2318 and #2490....
Physiogenex to present its obese NASH hamster model at Drug Discovery on Target 2022 conference in Boston, MA, Oct 19 – 20th

Physiogenex to present its obese NASH hamster model at Drug Discovery on Target 2022 conference in Boston, MA, Oct 19 – 20th

by François Briand | Oct 14, 2022 | 2022

Physiogenex will be presenting the effects of clinical benchmarks in its innovative obese NASH hamster model at the Discovery on Target in Boston, MA, USA, Oct 19th – Oct 20th, 2022. Meet our expert Dr François Briand, our Director of Research and Development during...
Physiogenex to present its obese NASH hamster model at the European Incretin Study Group 2022 meeting in Lausanne, Switzerland (Sept. 29th – Oct 1st)

Physiogenex to present its obese NASH hamster model at the European Incretin Study Group 2022 meeting in Lausanne, Switzerland (Sept. 29th – Oct 1st)

by François Briand | Sep 27, 2022 | 2022

Physiogenex will be presenting the cardiometabolic benefits of the GLP-1 receptor agonist semaglutide in its innovative obese NASH hamster model at the European Incretin Study Group 2022 meeting in Lausanne, Switzerland (Sept. 29th – Oct 1st). Meet Dr François...
Physiogenex to exhibit at booth#D04 and deliver 2 oral presentations at EASD 2022 in Stockholm, Sweden, Sept. 19-23 2022

Physiogenex to exhibit at booth#D04 and deliver 2 oral presentations at EASD 2022 in Stockholm, Sweden, Sept. 19-23 2022

by François Briand | Sep 15, 2022 | 2022

Physiogenex will be exhibiting at booth#D04 and presenting 2 oral abstracts at the EASD 2022 in Stockholm, Sweden Sept. 19-23. The first oral presentation, entitled “Time-restricted feeding and obeticholic acid/semaglutide drug combination have a different...
« Older Entries
Next Entries »

Physiogenex is a preclinical CRO providing original and benchmarked animal models of obesity/type 2 diabetes and related co-morbidities: NASH/fibrosis, dyslipidemia, inflammation, diabetic nephropathy and cardiovascular complications. For > 15 years, we have been evaluating the drugs’ efficacy of our clients using gold-standard and radio-tracer based experiments in our validated preclinical models. Our customers benefit from our experience in drug development and expertise in metabolic diseases, as demonstrated with our numerous co-publications with our industry partners.

For more information on our company and offers, please download our Corporate Presentation.

Menu

  • CRO Services
  • Consulting
  • Publications
  • News
  • Careers

Services

  • Obesity – Diabetes
  • NASH Preclinical
  • Dyslipidaemia Atherosclerosis
  • Diabetic Nephropathy
  • Nutraceuticals

Useful Menu

  • Accueil
  • Contact us
  • Site map
  • Legal mentions
  • Privacy Policy

Contact

PHYSIOGENEX S.A.S.

Address : 280 rue de l’Hers, ZAC de la Masquère, 31750 Escalquens – France
Phone : +33532097980

For general inquiries, please contact us here.

  • Twitter
  • RSS
Copyright © PHYSIOGENEX
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT